Ikarian Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ikarian Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,472	Closed	-$558K	–	179
2023 Q2	$558K	Sell	5,472 -75,092	-93%	-$7.11M	0.09%	97
2023 Q1	$7.32M	Buy	+80,564	New	+$4.73M	1.66%	19
2022 Q4	–	Sell	-4,064	Closed	-$140K	–	113
2022 Q3	$102K	Sell	4,064 -16,741	-80%	-$464K	0.02%	99
2022 Q2	$632K	Sell	20,805 -66,100	-76%	-$1.97M	0.12%	94
2022 Q1	$2.85M	Buy	+86,905	New	+$2.58M	0.37%	55
2021 Q2	–	Sell	-600	Closed	-$67.8K	–	313
2021 Q1	$60K	Buy	+600	New	+$70K	﹤0.01%	283

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ikarian Capital's RETA Position: Q3 2023 in Review

Ikarian Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 5,472 shares — an estimated $558K sold.

Ikarian Capital first reported a position in RETA in Q1 2021 and held it in 6 quarters. The position peaked at $7.32M in Q1 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Ikarian Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 5,472 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $558K.
Ikarian Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 6 quarters.
Ikarian Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7.32M in Q1 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.